Reshma Kewalramani, Vertex CEO (YouTube)

Ver­tex gets much-need­ed win with ‘ex­tra­or­di­nary’ first pa­tient re­sults on po­ten­tial di­a­betes cure

Ver­tex said Mon­day that the first pa­tient dosed with its cell ther­a­py for type 1 di­a­betes saw their need for in­sulin in­jec­tions van­ish al­most en­tire­ly, a key ear­ly step in the decades-long ef­fort to de­vel­op a cu­ra­tive treat­ment for the chron­ic dis­ease.

The pa­tient, who had suf­fered five po­ten­tial­ly life-threat­en­ing hy­po­glycemic — or low blood sug­ar — episodes in the year be­fore the ther­a­py, was in­ject­ed with syn­thet­ic in­sulin-pro­duc­ing cells. Af­ter 90 days, the pa­tient’s new cells pro­duced in­sulin steadi­ly and ramped up their in­sulin pro­duc­tion af­ter a meal like nor­mal cells do, as mea­sured by a stan­dard bio­mark­er for in­sulin pro­duc­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.